Alterity Therapeutics Limited (PRNAF)
OTCMKTS · Delayed Price · Currency is USD
0.0036
-0.0032 (-47.06%)
At close: Jul 25, 2024

Alterity Therapeutics Cash Flow Statement

Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2015
Period Ending
Jun '24 Jun '24 Jun '23 Jun '22 Jun '21 Jun '20 2019 - 2015
Net Income
-19.12-19.12-13.81-12.85-15.31-13.46
Upgrade
Depreciation & Amortization
0.150.150.10.050.080.11
Upgrade
Asset Writedown & Restructuring Costs
--0.01---
Upgrade
Stock-Based Compensation
0.880.880.971.511.88-0.01
Upgrade
Other Operating Activities
-0.26-0.26-0.92-2.810.43-0.26
Upgrade
Change in Accounts Receivable
4.624.62-3.94-0.45-4.224.77
Upgrade
Change in Accounts Payable
1.11.1-1.562.60.43-0.65
Upgrade
Change in Other Net Operating Assets
0.020.02-0.89-0.39-0.620.07
Upgrade
Operating Cash Flow
-12.61-12.61-20.04-12.34-17.33-9.43
Upgrade
Capital Expenditures
-0.01-0.01-0.01-0.09-0.01-0.02
Upgrade
Other Investing Activities
---0.03---
Upgrade
Investing Cash Flow
-0.01-0.01-0.04-0.09-0.01-0.02
Upgrade
Long-Term Debt Repaid
-0.01-0.01-0.06-0.03-0.06-0.09
Upgrade
Net Debt Issued (Repaid)
-0.01-0.01-0.06-0.03-0.06-0.09
Upgrade
Issuance of Common Stock
10.1410.140.3217.1839.244.36
Upgrade
Other Financing Activities
-0.92-0.92-0.13-0.84-2.49-0.29
Upgrade
Financing Cash Flow
9.229.220.1216.336.693.98
Upgrade
Foreign Exchange Rate Adjustments
0.260.260.912.81-0.430.26
Upgrade
Net Cash Flow
-3.13-3.13-19.036.6918.92-5.2
Upgrade
Free Cash Flow
-12.61-12.61-20.04-12.43-17.34-9.45
Upgrade
Free Cash Flow Margin
-313.78%-313.78%-511.78%-242.54%-399.59%-
Upgrade
Free Cash Flow Per Share
-0.00-0.00-0.01-0.01-0.01-0.01
Upgrade
Cash Interest Paid
0.010.010000
Upgrade
Cash Income Tax Paid
-8.53-8.530.1-4.08--4.82
Upgrade
Levered Free Cash Flow
-5.36-5.36-14.53-6.46-11.91-4.44
Upgrade
Unlevered Free Cash Flow
-5.36-5.36-14.53-6.46-11.91-4.44
Upgrade
Change in Net Working Capital
-5.87-5.876.43-1.764.38-4.18
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.